Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

Casein kinase: the triple meaning of a misnomer

(2014) Andrea Venerando et al.   BIOCHEMICAL JOURNAL

A “SYDE” effect of hierarchical phosphorylation: possible relevance to the cystic fibrosis basic defect

(2014) A. Venerando et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPAR  Down-Regulation

(2014) L. Maiuri et al.   JOURNAL OF IMMUNOLOGY

IFN-γ Stimulates Autophagy-Mediated Clearance of Burkholderia cenocepacia in Human Cystic Fibrosis Macrophages

(2014) Kaivon Assani et al.   PLoS One

New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate

(2014) Hae-Suk Kim et al.   Redox Biology

Phosphorylation of cystic fibrosis transmembrane conductance regulator (CFTR) serine-511 by the combined action of tyrosine kinases and CK2: the implication of tyrosine-512 and phenylalanine-508

(2013) Luca Cesaro et al.   AMINO ACIDS

Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator

(2013) V R Villella et al.   CELL DEATH AND DIFFERENTIATION

Kinase CK2 Inhibition: An Update

(2013) G. Cozza et al.   CURRENT MEDICINAL CHEMISTRY

Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis

(2013) Margarida D. Amaral et al.   CURRENT PHARMACEUTICAL DESIGN

Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi

(2013) Carlos M. Farinha et al.   FEBS Journal

Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs

(2013) David A. Stoltz et al.   JOURNAL OF CLINICAL INVESTIGATION

Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data

(2013) Frank J. Accurso et al.   Journal of Cystic Fibrosis

Dose-response plasma appearance of green tea catechins in adults

(2013) Mathieu Renouf et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Ivacaftor in a G551D Homozygote with Cystic Fibrosis

(2013) Michael J. Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Phospho-Sites Generated by Protein Kinase CK2 in CFTR: Mechanistic Aspects of Thr1471 Phosphorylation

(2013) Andrea Venerando et al.   PLoS One

Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect

(2013) Valeria Rachela Villella et al.   Frontiers in Pharmacology

Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator

(2012) Alessandro Luciani et al.   Autophagy

Inhibition of Protein Kinase CK2 by Flavonoids and Tyrphostins. A Structural Insight

(2012) Graziano Lolli et al.   BIOCHEMISTRY

Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses

(2012) Laura N. Vandenberg et al.   ENDOCRINE REVIEWS

Depletion of the Ubiquitin-binding Adaptor Molecule SQSTM1/p62 from Macrophages HarboringcftrΔF508 Mutation Improves the Delivery ofBurkholderia cenocepaciato the Autophagic Machinery

(2012) Basant A. Abdulrahman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Effect of Cysteamine Bitartrate on Adiponectin Multimerization in Non-Alcoholic Fatty Liver Disease and Healthy Subjects

(2012) Ranjan Dohil et al.   JOURNAL OF PEDIATRICS

Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor

(2011) Glenn S. Van Aller et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*

(2011) Robert Paine et al.   CRITICAL CARE MEDICINE

Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention

(2011) H. Yang et al.   CURRENT CANCER DRUG TARGETS

Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies

(2011) Margarida D. Amaral   CURRENT DRUG TARGETS

New clinical diagnostic procedures for cystic fibrosis in Europe

(2011) K. De Boeck et al.   Journal of Cystic Fibrosis

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients

(2011) Naïm Bouazza et al.   Orphanet Journal of Rare Diseases

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

(2011) F. Van Goor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation

(2011) J P Clancy et al.   THORAX

CFTR: folding, misfolding and correcting the ΔF508 conformational defect

(2011) Gergely L. Lukacs et al.   TRENDS IN MOLECULAR MEDICINE

Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition

(2010) Alessandro Luciani et al.   NATURE CELL BIOLOGY

The Proteome in Balance

(2010) D. Hutt et al.   SCIENCE

Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane

(2010) T. Okiyoneda et al.   SCIENCE

SUMOylation of Tissue Transglutaminase as Link between Oxidative Stress and Inflammation

(2009) A. Luciani et al.   JOURNAL OF IMMUNOLOGY

Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis

(2009) Darren M Hutt et al.   Nature Chemical Biology

Chloride channels as drug targets

(2009) Alan S. Verkman et al.   NATURE REVIEWS DRUG DISCOVERY

CFTR Function and Prospects for Therapy

(2008) John R. Riordan   Annual Review of Biochemistry

The challenge of developing green tea polyphenols as therapeutic agents

(2008) C. Huo et al.   INFLAMMOPHARMACOLOGY